Global Multi-Cancer Early Detection Market to Reach USD 5,517.4 Million by 2035 at 15.87% CAGR
Vectomat Insights releases a 10-year forecast on the Global Multi-Cancer Early Detection Market, highlighting liquid biopsy dominance, Medicare coverage momentum, and North America's 37.2% revenue share through 2035.
ST. CATHARINES, Ontario — November 14, 2026 — Vectomat Insights has published a comprehensive market research study projecting the global multi-cancer early detection (MCED) market to grow from USD 1,264.8 million in 2025 to USD 5,517.4 million by 2035, expanding at a 15.87% compound annual growth rate (CAGR).
Liquid biopsy leads technology share at 46.8% of 2025 revenue (USD 591.4 million) and expands fastest at a 19.68% CAGR, driven by single-draw blood screening platforms such as GRAIL's Galleri and Guardant's Shield MCD. By cancer application, lung cancer accounts for the largest revenue share at 22.0% and grows at 21.53% annually, while diagnostic laboratories represent the largest end-user segment at 38.6%.
From a regional perspective, North America leads global demand with a 37.2% market share in 2025 (USD 470.5 million), led by the United States at USD 395.5 million following the enactment of the Medicare MCED Screening Coverage Act and a favorable FDA advisory panel vote for Galleri. Asia-Pacific follows at 25.7% as the fastest-growing region through 2035, ahead of Europe at 25.5%.
Recent industry milestones reshaping the competitive landscape include Abbott's acquisition of Exact Sciences, Guardant Health's commercial launch of Shield MCD across key Asian markets with Manulife, and FDA Breakthrough Device Designation for Natera's MCED assay.
To preview key data tables and request a free sample of the 300-page report covering 35 countries and 14 company profiles, visit: https://www.vectomatinsights.com/request-sample?report=multi-cancer-early-detection-market
To select a license and purchase the full report, visit: https://www.vectomatinsights.com/checkout?report=multi-cancer-early-detection-market
About Vectomat Insights
Vectomat Insights is an independent market research firm providing analyst-validated intelligence across healthcare and life sciences. Sized bottom-up and validated top-down through an audited 16-step process, our reports deliver 10-year forecasts, country-level breakdowns, and competitive insights for strategic decision-makers.
Liquid biopsy leads technology share at 46.8% of 2025 revenue (USD 591.4 million) and expands fastest at a 19.68% CAGR, driven by single-draw blood screening platforms such as GRAIL's Galleri and Guardant's Shield MCD. By cancer application, lung cancer accounts for the largest revenue share at 22.0% and grows at 21.53% annually, while diagnostic laboratories represent the largest end-user segment at 38.6%.
From a regional perspective, North America leads global demand with a 37.2% market share in 2025 (USD 470.5 million), led by the United States at USD 395.5 million following the enactment of the Medicare MCED Screening Coverage Act and a favorable FDA advisory panel vote for Galleri. Asia-Pacific follows at 25.7% as the fastest-growing region through 2035, ahead of Europe at 25.5%.
Recent industry milestones reshaping the competitive landscape include Abbott's acquisition of Exact Sciences, Guardant Health's commercial launch of Shield MCD across key Asian markets with Manulife, and FDA Breakthrough Device Designation for Natera's MCED assay.
To preview key data tables and request a free sample of the 300-page report covering 35 countries and 14 company profiles, visit: https://www.vectomatinsights.com/request-sample?report=multi-cancer-early-detection-market
To select a license and purchase the full report, visit: https://www.vectomatinsights.com/checkout?report=multi-cancer-early-detection-market
About Vectomat Insights
Vectomat Insights is an independent market research firm providing analyst-validated intelligence across healthcare and life sciences. Sized bottom-up and validated top-down through an audited 16-step process, our reports deliver 10-year forecasts, country-level breakdowns, and competitive insights for strategic decision-makers.
- Contact Email
- [email protected]
- Issued By
- Vectomat Insights
- Website
- Vectomat Insights
- Phone
- +1 416-876-0312
- Business Address
- • 6 ½ Smythe Street, St. Catharines, ON L2P 2G8, Canada
- Country
- Canada
- Categories
- Health · Medical · Pharma
- Last Updated
- November 14, 2026